SGM Alliance is a 501(c)(3) nonprofit organization dedicated to educating and advocating for the inclusion of Sexual and Gender Minorities (SGM) in healthcare. We work to ensure that all individuals have equitable access to quality care, clinical research, and life-saving treatments.

SGM stands for Sexual and Gender Minorities, which includes—but is not limited to—individuals who identify as lesbian, gay, bisexual, transgender, queer, and/or intersex. It also includes those who may not fit into traditional labels but experience health disparities due to their sexual orientation, gender identity, or sex characteristics.

Historically, SGM individuals have been excluded from healthcare studies, clinical trials, and even general medical guidelines. This affects drug development, treatment access, and overall health outcomes. Without inclusive research, medications and treatments may not work as effectively for everyone. We work to change that by advocating for policies, research practices, and education that reflect the diversity of all patients.

SGM Alliance was founded on March 29, 2023, after discovering that outdated policies from the 1990s still excluded people living with HIV and those on PrEP from participating in clinical trials—including life-saving cancer trials. March 29 was also the first day we publicly spoke about this issue, marking the beginning of our movement for change.

Clinical research studies how new treatments, medications, and medical devices work in real people. It is essential for drug development and ensuring that treatments are safe and effective. However, many clinical trials have historically excluded marginalized communities, leading to gaps in knowledge and inequities in healthcare. We advocate for inclusive research that truly represents all patients.

Everyone’s body metabolizes medications differently, and factors like hormones, genetics, and overall health impact how treatments work. If SOGI data isn’t collected, healthcare professionals may not have the full picture when prescribing treatments.

Additionally, social determinants of health—such as access to healthcare, experiences of discrimination, and financial stability—impact health outcomes. For example, an individual’s ability to afford medication or find a provider who understands their needs can affect how well a treatment works. Collecting SOGI data helps address these gaps and create better healthcare solutions for all.

We welcome all supporters! Whether you want to volunteer, partner with us, or become an advocate, there are many ways to help. Contact us at info@sgmalliance.org to learn more about opportunities.

Absolutely! We’re always looking for passionate individuals who want to make a difference in healthcare equity.
Reach out to volunteer@sgmalliance.org for volunteer opportunities.

We offer corporate partnerships and sponsorship opportunities to companies that want to drive meaningful change. Whether it’s funding research initiatives, supporting education programs, or collaborating on inclusive healthcare policies, your company can play a role in improving health equity. If your organization wants to support our mission, email us at allyship@sgmalliance.org.

We work globally with healthcare providers, pharmaceutical companies, regulatory agencies, and policymakers to update outdated language, remove discriminatory exclusions in clinical research, and push for inclusive healthcare guidelines. We also educate professionals on best practices for SGM inclusion.

Yes! We provide resources, webinars, and guidance for healthcare professionals, researchers, and clinical trial sponsors on how to create inclusive healthcare environments. Contact us to learn more about our education initiatives.

Not all clinical trials are inclusive yet, but we’re working to change that. If you’re considering participating in a trial, ask if they collect SOGI (Sexual Orientation and Gender Identity) data and whether they allow individuals on PrEP, people living with HIV, or gender-diverse patients to enroll. We also advocate for transparency in trial eligibility criteria.